Abstract
Calcific aortic valve disease (CAVD) is the most frequent form of val-vular pathology [1,2], with high percentages of mortality and morbidityin Western populations, so much to be a very public health problem [2].Diverse millions of subjects are affected by CAVD and the major numberare old individuals (65- older), even if some have a younger age and aregenerally affected by congenital bicuspid aortic valve (BAV) disease[2,3]. CAVD in BAV individuals arises decades earlier respect to subjectswith the physiological tricuspid aortic valve [3]. Furthermore, it can leadto death if untreated with surgical aortic valve replacement or trans-catheter aortic valve implantation, its unique treatments [2]. No phar-macological drugs have been developed for CAVD, because itspathophysiology remains unknown, with mechanisms and pathwaysfully questionable [
Lingua originale | English |
---|---|
pagine (da-a) | 108-109 |
Numero di pagine | 2 |
Rivista | INTERNATIONAL JOURNAL OF CARDIOLOGY |
Volume | 309 |
Stato di pubblicazione | Published - 2020 |
All Science Journal Classification (ASJC) codes
- Cardiology and Cardiovascular Medicine